NY-CONCIERGE-AUCTIONS
30.5.2019 16:19:04 CEST | Business Wire | Press release
A 16,000-square-foot Oak Glen mountain chalet will auction next month via Concierge Auctions’ online marketplace. Situated on 845 acres among surrounding mountains at 6,000 feet, the property – known as Eagle Crest – is the highest individually owned mountaintop compound in Southern California. Currently listed for $21.5 million, 40288 Pine Bench Road will auction Without Reserve in cooperation with Craig Strong of Compass. Buyers may bid from anywhere in the world June 26th -28th via the firm’s global online marketplace.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190530005547/en/
“The auction presents an incredible opportunity to own a serene retreat in the mountains of Southern California,” said Strong. “The estate offers one-of-a-kind custom work throughout sourced from artists and locations around the world. To reproduce a home with this craftsmanship and detail would require many years and an extensive budget.”
Architectural features of the five-bedroom estate include vaulted wood ceilings, abundant large windows with views to the ocean, custom distressed Alder cabinetry, more than 69 tons of naturally chiseled 3-Rivers stone flooring quarried from the Wasatch Mountain Range, and custom solid wood interior doors manufactured by Craftsman in Wood.
The interiors boast a commercial grade kitchen with top appliances such as Braun, Bosch, Sub Zero, and Wolfe; dining room framed by large floor-to-ceiling rock columns; master suite with a hand carved mantel, fireplace, coffee bar, two outdoor decks facing the north and south, dry sauna, and a privacy deck with a built-in Jacuzzi; a separate self-contained VIP suite with kitchen, a cinema with ticket booth and seating for 17 viewers, billiards room with nine-foot Brunswick tournament pool table, wine room with Sub-Zero wine cabinet, commercial-style fitness center with a Pilates and tanning room, and a 4,100-square-foot six-bay garage, shop, and carport.
Outdoor amenities include a dramatic 150-foot natural rock river bed that can be turned into a flowing waterscape, two barns, caretaker’s home, stocked fishing pond, full water rights tested and approved by Arrowhead Water, and an endless 845-acre backcountry.
For more information, visit ConciergeAuctions.com or call +1.212.202.2940.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190530005547/en/
Contact:
Kari Neering kari@relevanceinternational.com David Gautschy david@relevanceinternational.com (212) 257-1500
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom